Detalhe da pesquisa
1.
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Ann Oncol
; 26(5): 914-920, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25722380